← Back to Search

Unknown

ADX-629 for Chronic Cough

Phase 2
Waitlist Available
Research Sponsored by Aldeyra Therapeutics, Inc.
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up day 1 - 14 of each treatment period

Summary

This trial tests ADX-629, an oral medication, on patients with chronic cough that doesn't respond to usual treatments or has no known cause. It aims to see if the medication can safely and effectively reduce their coughing symptoms.

Eligible Conditions
  • Chronic Cough
  • Chronic Bronchitis

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~from baseline to the end of each 14-day treatment period (day 1 - 14 of each treatment period)
This trial's timeline: 3 weeks for screening, Varies for treatment, and from baseline to the end of each 14-day treatment period (day 1 - 14 of each treatment period) for reporting.

Treatment Details

Study Objectives

Study objectives can provide a clearer picture of what you can expect from a treatment.
Primary study objectives
Number of participants with adverse events (AEs)
Secondary study objectives
Change from baseline in awake cough frequency after 2-week treatment period

Trial Design

2Treatment groups
Experimental Treatment
Placebo Group
Group I: ADX-629Experimental Treatment1 Intervention
Subjects will be randomized to receive ADX-629 300mg tablets administered orally twice a day for 14 days.
Group II: PlaceboPlacebo Group1 Intervention
Subjects will be randomized to receive matching placebo tablets administered orally twice a day for 14 days.
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
ADX-629
2021
Completed Phase 2
~110

Find a Location

Who is running the clinical trial?

Aldeyra Therapeutics, Inc.Lead Sponsor
32 Previous Clinical Trials
4,619 Total Patients Enrolled
~14 spots leftby Nov 2025